

1 March 2021

ASX Announcement

Investor briefing notification

MELBOURNE Australia, 1 March 2021: AdAlta Limited (ASX: 1AD), the biotechnology company using its i-body technology to develop drug candidates against hard to drug targets, will hold an investor briefing in Melbourne on 10 March 2021.

AdAlta is pleased to invite you to a special investor/analyst briefing. At the briefing, CEO Tim Oldham, VP Clinical Product Development Claudia Gregorio-King and Prof Glen Westall, a leading respiratory and lung fibrosis specialist, will discuss the Company's strategic progress and top-line results from Part A of the Phase I trial of AD-214.

CEO of AdAlta, Dr Tim Oldham commented, "The investor briefing is an opportunity for AdAlta to update investors on AdAlta's strategic progress, especially the significant progress of our AD-214 clinical program".

The AdAlta team will discuss:

- AdAlta's progress against its strategic plan
- AD-214 top-line results from Phase I Part A (healthy volunteer single dose) trial
- Next steps for Phase I program and other pipeline expansion opportunities.

Date: Wednesday 10th March 2021

Time: 11 am –12.15 pm

Venue: K&L Gates, Level 25 South Tower, 525 Collins St, Melbourne (limited seats)

Online: Webex webinar platform – register to receive link prior to the event

Those investors interested in attending in person or online are invited to register interest with Lauren Byrne via lauren.byrne@irdepartment.com.au by Friday the 5th of March 2021.

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
March 2021

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is conducting Phase 1 clinical studies for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to discover i-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immuno-oncology drugs.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: www.adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au